galapagos nv investor relations
29 April 2022. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. GALAPAGOS AKTIE Unternehmensprofil | Aktionärsstruktur | A0EAT9 Net loss of €119.6million. AKZO.AS. Executive Assistant. Investor relations calendar The number of employees at Galapagos NV at the end of 2019 amounted to 361 as compared to 261 at the end of 2018, excluding insourced personnel. Depreciation increased to €403.3 million in 2019, compared to €305.7 million in 2018, and related primarily to amortization of R&D expenses. Company. Investor Relations Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 [email protected] Richard Blickman, CEO Hetwig van Kerkhof, SVP Finance Leon Verweijen, VP Finance Claudia Vissers, Executive Secretary/ IR coordinator Tel: + 31 26 319 4500 Contact us. The burden of inflammatory bowel disease in Europe. Share Price Ticker. Galapagos Investor Relations Galapagos NV 0JXZ Morningstar Rating Rating as of Apr 13, 2022. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Galapagos Genomics NV
Fit Für Tests Und Klassenarbeiten Découvertes 3 Lösungen,
Articles G